CASI Pharmaceuticals Overview
- Year Founded
-
1991
- Status
-
Public
- Employees
-
214
- Stock Symbol
-
CASIF
- Investments
-
11
- Share Price
-
$0.10
- (As of Friday Closing)
CASI Pharmaceuticals General Information
Description
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
Contact Information
Website
www.casipharmaceuticals.comCorporate Office
- Room 1701-1703, Tower 1, Huamao Office Building
- Number 81, Jianguo Road, Chaoyang District
- Beijing, 100025
- China
Corporate Office
- Room 1701-1703, Tower 1, Huamao Office Building
- Number 81, Jianguo Road, Chaoyang District
- Beijing, 100025
- China
CASI Pharmaceuticals Stock Performance
As of 13-Nov-2026, CASI Pharmaceuticals’s stock price is $0.10. Its current market cap is $2.1M with 20.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.10 | $0.10 | $0.05 - $1.35 | $2.1M | 20.6M | 2.4K | -$2.00 |
CASI Pharmaceuticals Financials Summary
As of 30-Jun-2026, CASI Pharmaceuticals has a trailing 12-month revenue of $20.1M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 25,348 | 31,636 | 42,153 | 81,425 |
| Revenue | 20,114 | 20,712 | 28,537 | 33,879 |
| EBITDA | (43,938) | (35,376) | (23,119) | |
| Net Income | (43,959) | (48,058) | (39,258) | (26,938) |
| Total Assets | 21,063 | 25,650 | 53,674 | 75,268 |
| Total Debt | 40,497 | 27,486 | 22,141 | 21,239 |
CASI Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CASI Pharmaceuticals Comparisons
Industry
Financing
Details
CASI Pharmaceuticals Competitors (52)
One of CASI Pharmaceuticals’s 52 competitors is Lava Therapeutics, a Formerly VC-backed company based in Utrecht, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lava Therapeutics | Formerly VC-backed | Utrecht, Netherlands | ||||
| AVEO Oncology | Formerly VC-backed | Boston, MA | ||||
| Alaunos Therapeutics | Formerly VC-backed | Fort Lauderdale, FL | ||||
| Ayala Pharmaceuticals | Corporation | Wilmington, DE | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom |
CASI Pharmaceuticals Patents
CASI Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022388575-A1 | Vcp/p97 inhibitor for the treatment of cancer | Inactive | 10-Nov-2021 | ||
| EP-4429772-A1 | Vcp/p97 inhibitor for the treatment of cancer | Pending | 10-Nov-2021 | ||
| EP-4429772-A4 | Vcp/p97 inhibitor for the treatment of cancer | Pending | 10-Nov-2021 | ||
| US-20250049800-A1 | Vcp/p97 inhibitor for the treatment of cancer | Pending | 10-Nov-2021 | ||
| AU-2021338773-A1 | Methods of blood screening | Pending | 10-Sep-2020 | G01N33/80 |
CASI Pharmaceuticals Signals
CASI Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
CASI Pharmaceuticals Investments & Acquisitions (11)
CASI Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with CASI Pharmaceuticals (CB-5339). The deal was made on 21-Jul-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CASI Pharmaceuticals (CB-5339) | 21-Jul-2023 | Corporate Asset Purchase | Drug Delivery | ||
| Precision Autoimmune Therapeutics | 05-Jul-2022 | Early Stage VC | Drug Discovery | ||
| Juventas (Drug Discovery) | 30-Sep-2020 | Early Stage VC | Drug Discovery | ||
| Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) | 03-Dec-2019 | Corporate Asset Purchase | Buildings and Property | ||
| Juventas (Drug Discovery) | 01-Jun-2019 | Early Stage VC | Drug Discovery |
CASI Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
CASI Pharmaceuticals Exits (1)
CASI Pharmaceuticals’s most recent exit was on 07-Apr-2004 from MaxCyte. The exit was categorized as with 4 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| MaxCyte | 07-Apr-2004 | Completed |
|
CASI Pharmaceuticals FAQs
-
When was CASI Pharmaceuticals founded?
CASI Pharmaceuticals was founded in 1991.
-
Where is CASI Pharmaceuticals headquartered?
CASI Pharmaceuticals is headquartered in Beijing, China.
-
What is the size of CASI Pharmaceuticals?
CASI Pharmaceuticals has 214 total employees.
-
What industry is CASI Pharmaceuticals in?
CASI Pharmaceuticals’s primary industry is Drug Discovery.
-
Is CASI Pharmaceuticals a private or public company?
CASI Pharmaceuticals is a Public company.
-
What is CASI Pharmaceuticals’s stock symbol?
The ticker symbol for CASI Pharmaceuticals is CASIF.
-
What is the current stock price of CASI Pharmaceuticals?
As of 13-Nov-2026 the stock price of CASI Pharmaceuticals is $0.10.
-
What is the current market cap of CASI Pharmaceuticals?
The current market capitalization of CASI Pharmaceuticals is $2.1M.
-
What is CASI Pharmaceuticals’s current revenue?
The trailing twelve month revenue for CASI Pharmaceuticals is $20.1M.
-
Who are CASI Pharmaceuticals’s competitors?
Lava Therapeutics, AVEO Oncology, Alaunos Therapeutics, Ayala Pharmaceuticals, and Immunocore Holdings are some of the 52 competitors of CASI Pharmaceuticals.
-
What is CASI Pharmaceuticals’s annual earnings per share (EPS)?
CASI Pharmaceuticals’s EPS for 12 months was -$2.00.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process